The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
申请公布号
AU2014295143(B9)
申请公布日期
2017.03.23
申请号
AU20140295143
申请日期
2014.07.22
申请人
BASF SE
发明人
Hafner, Andreas;Blatter, Fritz;Szelagiewicz, Martin;Siebenhaar, Bernd;Chiodo, Tiziana;Hintermann, Tobias;Salvador, Beate;Vossen, Marcus